Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 5F32HL143916 | U.S. NIH Grant/Contract | View source | |
| 856341 | Other Grant/Funding Number | American Heart Association |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
| American Heart Association | OTHER |
Not provided
Not provided
Not provided
The goal of this observational study is to learn about the composition and function of the gut microbiome in adults with chronic heart failure with reduced ejection fraction. The main questions the study aims to answer are:
During this study, investigators will recruit adults diagnosed with chronic heart failure with reduced ejection fraction caused by non-ischemic cardiomyopathy. These individuals will undergo longitudinal profiling. This will include detailed profiling of their (1) gut microbiome, (2) blood metabolic and immune markers, and (3) heart failure clinical status. Integrated results will lead to deeper understanding of how gut microbiome interacts with and affects the host in chronic heart failure.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Heart failure | Adults with heart failure with reduced ejection fraction; no intervention |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Advanced heart failure-associated microbiome signatures | A map of gut microbiome compositional and functional features associated with a composite clinical outcome of advanced heart failure (composite of needing heart transplantation (including active listing), left ventricular assist device implantation, transition to hospice, or death) that occurs within 24 months of baseline visit. Fecal samples will be collected every 3 months over the first 12 month period. Microbiota composition will be determined by shotgun metagenomic sequencing, with taxonomic and metabolic pathway signatures generated using bioinformatic pipelines, respectively. Comprehensive microbiome signatures will encompass alpha and beta diversity, and differential abundance analysis. | 24 months from baseline visit |
| Temporal changes in the gut microbiome community composition in chronic heart failure | Longitudinal changes in the gut microbiome composition and functionality in chronic heart failure will be determined. Microbiome signatures will be mapped from fecal samples collected every 3 months over a 12 month period, generated from shotgun metagenomic sequencing data and after processing through bioinformatic pipelines. | 12 months from baseline visit |
| Measure | Description | Time Frame |
|---|---|---|
| Comprehensive longitudinal metabolome profile in chronic heart failure | Changes in the host (human) metabolome profile in chronic heart failure with reduced ejection fraction will be determined. Participants provide fasting blood samples every 3 months for 12 months, from which plasma samples are prepared. Plasma metabolites are run through liquid chromatography-mass spectrometry (LC-MS) columns. MetID (Metabolite Identification from a reference database) and our LC-MS data are used to identify hundreds of metabolites with confidence levels 1-2. Many of the identified metabolites are gut microbiome-derived. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Adults diagnosed with heart failure with reduced ejection fraction due to non-ischemic cardiomyopathy will be recruited from outpatient cardiomyopathy/heart failure clinic.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University | Stanford | California | 94305-5210 | United States |
De-identified clinical data, gut microbiome (taxonomic and metabolic pathway) profiles, plasma metabolome and cytokines (see details below), in addition to analytical code
Immediately upon publication, without end date
All nucleic acid raw read and processed data will be deposited in Sequence Read Archive (SRA) (metagenomics). Metabolomics and cytokine data will be deposited in Metabolomics Workbench and ImmPort (both of these are National Institutes of Health (NIH) data repositories), respectively. All genomic data sharing will be done in accordance with NIH policies, including the Genomic Data Sharing Policy, and the Institutional Review Board (IRB) approved consent types for each sample type. Detailed metadata will be associated with each dataset. To request access of the data, researchers will use the standard processes at the above repositories. The standard data access processes typically allow access for one year and are renewable. Once the data are submitted to the above repositories, those archive will control the long-term persistence of the data set.
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Stool samples, fasting plasma and serum
| 12 months from baseline visit |
| Comprehensive longitudinal cytokine profile in chronic heart failure | Changes in the host (human) cytokines in chronic heart failure with reduced ejection fraction will be determined. Participants provide fasting blood samples every 3 months for 12 months, from which serum samples are prepared. Cytokines are profiled using a 76-cytokine Luminex profiling system at the Stanford Human Immune Monitoring Center. This involves attaching antibodies specific to cytokines to beads using a capture molecule. The fluorescent molecules are attached to the cytokines, and fluorescence is used as the measure of cytokine abundance. | 12 months from baseline visit |
| Longitudinal change in New York Heart Association (NYHA) functional class | Participants' functional status (as measured by NYHA class, which ranges from 1 to 4, with 1 being no to minimal symptoms with activity, and 4 being symptoms at rest) will be assessed at each study visit for the first 12 months (every 3 months). | 12 months from baseline visit |
| Longitudinal change in the self-reported functional status | Participant self-reported functional status will be assessed via Kansas City Cardiomyopathy Questionnaire-12, which participant will complete at each study visit (every 3 months for 12 months). Overall summary and clinical summary scores (each 0-100, with 0 corresponding to severe and 100 corresponding to no functional limitations) will be calculated and compared over visits. | 12 months from baseline visit |